

**Technology Advisory Interests Register**

**Topic: Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]**

**Publication Date: 7 May 2026**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Susanna Banerjee	Clinical Expert	Direct – financial	Payment for advisory boards, education events/lectures from Abbvie  Indirect Yes -was a	09/02/2026	It was agreed that Susanna’s declaration would not prevent her from providing expert advice to the committee
		Direct – non-financial	UK Coordinating Investigator (CI) for the MIRASOL trial (indication of this appraisal), co-author of publication		
		Indirect	Was a chief investigator for Mirvetuximab Trial in UK		

Patrick De Barr	TAC Committee Member	Financial	<p>Patrick is employed by GSK who produce a PARP inhibitor (niraparib) which forms part of the treatment pathway for ovarian cancer.</p> <p>GSK are about to start a phase 3 in PROC.</p> <p>Patrick is employed by GSK who manufacture a parp inhibitor licensed for use in ovarian cancer. GSK are not listed as a comparator.</p> <p>Patrick is an employed by GSK who produce a PARP inhibitor (niraparib) which forms part of the treatment pathway for ovarian cancer.</p>	09/03/2026 19/02/2026 14/10/2025	It was agreed that Patrick's declaration would prevent him from participating in discussions on this appraisal
Becky Pennington	TAC Committee Member	Direct – Financial	Becky has an ongoing methods research project with Pfizer on carers' HRQoL, paid to her employer UoS.	12/02/2026	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal
Zoe Phillips	TAC Committee Member	Financial	Zoe has provided paid consultancy to the company on this topic	12/02/2026 16/10/2025	It was agreed that Zoe's declaration would prevent her from participating in discussions on this appraisal
Dominic Pivonka	TAC Committee Member	Financial	Dominic's employer (AbbVie) is the company sponsor	16/02/2025 17/10/2025	It was agreed that Dominic's declaration would prevent him from participating in discussions on this appraisal

Prof. Jonathan Ledermann	Expert	Financial	<p><b>Advisory Boards</b> AbbVie/Immunogen, AstraZeneca, Clovis Oncology, GSK, Merck/MSD, Bristol Myers Squibb, Nuvation, Immagine, Novocure,</p> <p><b>Speaker Fees:</b> AstraZeneca; MSD/Merck; GSK; Medison, Independent Data Monitoring Committee Mersana; Sutro Bio; Zentalis; AstraZeneca</p> <p><b>Clinical Research Grants</b> AstraZeneca, MSD/Merck Research</p>	28/05/2025	It was agreed that Jonathan's declaration would not prevent him from providing expert advice to the committee
		Non-financial	Trustee Cancestry		
Rachel Downing	Expert	Financial	Target Ovarian Cancer has received a donation from AbbVie for their support services	04/11/2025	It was agreed that Rachel's declaration would not prevent her from providing expert advice to the committee
Victoria Clare	Expert	Financial	Ovacome have received grants from AbbVie and industry partners.	04/11/2025	It was agreed that Victoria's declaration would not prevent her from providing expert advice to the committee
Agnieszka Michael	Expert	Financial	I have previously received scientific grants from other companies, but have not received any funding from AbbVie.	04/11/2025	It was agreed that Agnieszka's declaration would not prevent her from providing expert advice to the committee

